Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects

Journal of Cellular Biochemistry

Volumn 66, Issue 3, 1997, Pages 413-425

  Campbell, Moray J ^a,c   Reddy, G Satyanarayana ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

24 oxo metabolites; Apoptosis; Differentiation; Growth inhibition; Vitamin D3 analogs

Indexed keywords

COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; 1,25 DIHYDROXY 16 ENE VITAMIN D3; 1,25 DIHYDROXY 24 OXO VITAMIN D3; 1,25-DIHYDROXY-16-ENE-VITAMIN D3; 1,25-DIHYDROXY-24-OXO-VITAMIN D3; BRCA1 PROTEIN; CADHERIN; CALCITRIOL; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DRUG DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; GROWTH REGULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; BREAST TUMOR; CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL STRAIN HL 60; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; MALE; METABOLISM; NEOPLASM; PROSTATE TUMOR;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BRCA1 PROTEIN; BREAST NEOPLASMS; CADHERINS; CALCITRIOL; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CHOLECALCIFEROL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; HL-60 CELLS; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0030611005     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19970901)66:3<413::AID-JCB13>3.0.CO;2-F     Document Type: Article

References (51)

1. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F (1995): E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. Embo J 14:6107-6115.
2. 3 analogues: A novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 42:1569-1575.
3. Brenner RV, Shabahang M, Schumaker LM, Nauta RJ, Uskokovic MR, Evans SR, Buras RR (1995): The antiproliferative effect of vitamin D analogs on MCF-7 human breast cancer cells. Cancer Lett 92:77-82.
4. 3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells. J Steroid Biochem Mol Biol 59:405-412.
5. (kipl) and E-cadherin. J Mol Endocrinol (in press).
6. Chen Y, Chen C-F, Riley DJ, Allred DC, Chen P-L, Von Hoff D, Osborne CK, Lee W-H (1995): Aberrant subcellular localization of BRCA1 in breast cancer. Science 270:789-791.
7. 3 is due to reduced catabolism and altered protein binding. Biochem Pharmacol 47:987-993.
8. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H (1996): Germline mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56:471-474.
9. 3: An extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood 84:1960-1967.
10. 3 analogues: A novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55:2822-2830.
11. 3 analogs and 9-cis retinoic acid. J Clin Invest 99:1-12.
12. Fang R, Orend G, Watanabe N, Hunter T, Rouslahti E (1996): Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271:499-502.
13. Feldman D, Skowronski RJ, Peehl DM (1995): Vitamin D and prostate cancer. Adv Exp Med Biol 375:53-63.
14. Hengst L, Reed S (1996): Translational control of p27 accumulation during the cell cycle. Science 271:1861-1864.
15. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King M-C, Jensen RA (1996): Growth retardation and tumour inhibition by BRCA1. Nat Genet 12:298-302.
16. James SY, Mackay AG, Binderup L, Colston KW (1994): Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 141:555-563.
17. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, Tronick SR, Page DL, King MC, Holt JT (1996): BRCA1 is secreted and exhibits properties of a granin. Nat Genet 12:303-308.
18. 3 is a potent antileukemic agent with low potential to cause hypercalcemia. Leuk Res 18:453-463.
19. 3, exerts immunosuppressive activity equal to its parent without causing hypercalcaemia in vivo. Endocrinology 135:2818-2820.
20. Li CJ, Wang C, Pardee AB (1995): Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res 55:3712-3715.
21. Li X, Daryzynkiewicz Z (1995): Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif 28:571-579.
22. Liu CY, Flesken-Nikitin A, Li S, Zeng Y, Lee WH (1996a): Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev 10:1835-1843.
23. Liu L, Shack S, Stetler-Stevenson WG, Hudgins WR, Samid D (1994): Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol 103:335-340.
24. Liu M, Lee M, Cohen M, Bommakanti M, Freedman L (1996b): Transcriptional activation of the Cdk inhibitor p21 by vitamin D leads to the induced differentiation of the myelomonocytic cell line U-937. Genes Dev 10:142-153.
25. 3 receptor. Mol Endocrinol 10:206-215.
26. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM (1995): The nuclear receptor superfamily: The second decade. Cell 83:835-839.
27. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA (1995): The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11: 17-26.
28. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H (1994): A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71.
29. Munker R, Norman A, Koeffler HP (1986): Vitamin D compounds. J Clin Invest 78:424-430.
30. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP (1996): A new series of vitamin D analogues is highly active for clonal inhibition, differentiation and induction of WAF1 in myeloid leukaemia. Blood 88:2201-2209.
31. 3: Towards an endocrine therapy of brain tumors? J Neurosci Res 37:271-277.
32. Niles RM (1995): Use of vitamins A and D in chemoprevention and therapy of cancer: Control of nuclear receptor expression and function. Vitamins, cancer and receptors. Adv Exp Med Biol 375:1-15.
33. 3. Differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res 50:6857-6864.
34. Novichenko N, Konno S, Nakajima Y, Hsieh TC, Xu W, Turo K, Ahmed T, Chiao JW (1995): Growth attenuation in a human prostate cell line mediated by a phorbol ester. Proc Soc Exp Biol Med 209:152-156.
35. Peleg S, Abruzzese RV, Cooper CW, Gagel RF (1993): Downregulation of calcitonin gene transcription by vitamin D requires two widely separated enhancer sequences. Mol Endocrinol 7:999-1008.
36. Samid D, Shack S, Myers CE (1993): Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91:2288-2295.
37. 3. Cancer Res 54:4057-4064.
38. Sitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ (1996): Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 105:394-402.
39. 3 into their respective lactones. Endocrinology 136:4195-4203.
40. 3. Endocrinology 136:20-26.
41. Su L, Vogelstein B, Kinzler K (1993): Association of the APC tumor suppressor protein with catenins. Science 262: 1734-1737.
42. Tamm I, Cardinale I, Kikuchi T, Krueger JG (1994): E-cadherin distribution in interlukin-6 induced cell-cell separation of ductal breast carcinoma cells. Proc Natl Acad Sci U S A 91:4338-4442.
43. Thomas MG, Brown GR, Alison MR, Williamson RC (1994): Divergent effects of epidermal growth factor and calcipotriol on human rectal cell proliferation. Gut 35:1742-1746.
44. 3 modulates the expression of a lymphokine (granulocyte-macrophage colony-stimulation factor) posttranscriptionally. J Clin Invest 81:1819-1823.
45. Upadhyay S, Li G, Liu H, Chen YQ, Sarkar FH, Kim HR (1995): Blc-2 suppresses expression of p21 WAF-1/CIPI in breast epithelial cells. Cancer Res 55:4250-4524.
46. 3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res 55:3050-3054.
47. Wang J, Walsh K (1996): Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273:359-361.
48. 3 in HL60 cells. Cancer Res 56:264-267.
49. Welsh J (1994): Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 72:537-545.
50. Yu J, Papavasiliou V, Rhim J, Goltzman D, Kremer R (1995): Vitamin D analogs: New therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs 6:101-108.
51. Yang NN, Venugopalan M, Hardikar S, Glasebrook A (1996): Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273:1222-1225.